ArticleAnnals of medicine and surgery (2012)2026
FDA expanded approval of Pluvicto (Lutetium-177 vipivotide tetraxetan) in metastatic castration-sensitive prostate cancer.
Malakia Saqib et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.